GB202020602D0 - Nanobody - Google Patents

Nanobody

Info

Publication number
GB202020602D0
GB202020602D0 GBGB2020602.5A GB202020602A GB202020602D0 GB 202020602 D0 GB202020602 D0 GB 202020602D0 GB 202020602 A GB202020602 A GB 202020602A GB 202020602 D0 GB202020602 D0 GB 202020602D0
Authority
GB
United Kingdom
Prior art keywords
nanobody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2020602.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Birmingham
Original Assignee
University of Birmingham
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Birmingham filed Critical University of Birmingham
Priority to GBGB2020602.5A priority Critical patent/GB202020602D0/en
Publication of GB202020602D0 publication Critical patent/GB202020602D0/en
Priority to US18/269,308 priority patent/US20240067721A1/en
Priority to CA3203202A priority patent/CA3203202A1/en
Priority to PCT/EP2021/087129 priority patent/WO2022136457A1/en
Priority to EP21844966.8A priority patent/EP4267624A1/en
Priority to CN202180094483.4A priority patent/CN117043191A/zh
Priority to JP2023538767A priority patent/JP2024500946A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GBGB2020602.5A 2020-12-24 2020-12-24 Nanobody Ceased GB202020602D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB2020602.5A GB202020602D0 (en) 2020-12-24 2020-12-24 Nanobody
US18/269,308 US20240067721A1 (en) 2020-12-24 2021-12-21 Nanobody to glycoprotein vi
CA3203202A CA3203202A1 (en) 2020-12-24 2021-12-21 Nanobody to glycoprotein vi
PCT/EP2021/087129 WO2022136457A1 (en) 2020-12-24 2021-12-21 Nanobody to glycoprotein vi
EP21844966.8A EP4267624A1 (en) 2020-12-24 2021-12-21 Nanobody to glycoprotein vi
CN202180094483.4A CN117043191A (zh) 2020-12-24 2021-12-21 糖蛋白vi的纳米抗体
JP2023538767A JP2024500946A (ja) 2020-12-24 2021-12-21 糖タンパク質viに対するナノボディ

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2020602.5A GB202020602D0 (en) 2020-12-24 2020-12-24 Nanobody

Publications (1)

Publication Number Publication Date
GB202020602D0 true GB202020602D0 (en) 2021-02-10

Family

ID=74532190

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2020602.5A Ceased GB202020602D0 (en) 2020-12-24 2020-12-24 Nanobody

Country Status (7)

Country Link
US (1) US20240067721A1 (cg-RX-API-DMAC7.html)
EP (1) EP4267624A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024500946A (cg-RX-API-DMAC7.html)
CN (1) CN117043191A (cg-RX-API-DMAC7.html)
CA (1) CA3203202A1 (cg-RX-API-DMAC7.html)
GB (1) GB202020602D0 (cg-RX-API-DMAC7.html)
WO (1) WO2022136457A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026019685A1 (en) * 2024-07-17 2026-01-22 Harpoon Therapeutics, Inc. Her2 targeting trispecific protein for treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130543D0 (en) * 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
US20090130021A1 (en) * 2002-06-07 2009-05-21 Gotz Munch Methods, products and uses involving platelets and/or the vasculature
WO2007091719A1 (ja) * 2006-02-07 2007-08-16 Mochida Pharmaceutical Co., Ltd. 抗gpvi抗体の併用療法及び新規医薬用途
EP1916259A1 (en) * 2006-10-26 2008-04-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
JP5843783B2 (ja) * 2009-12-18 2016-01-13 サノフイ GPVIに対する新規アンタゴニスト抗体および該抗体のFabフラグメントならびにこれらの使用

Also Published As

Publication number Publication date
CN117043191A (zh) 2023-11-10
EP4267624A1 (en) 2023-11-01
WO2022136457A1 (en) 2022-06-30
US20240067721A1 (en) 2024-02-29
CA3203202A1 (en) 2022-06-30
JP2024500946A (ja) 2024-01-10

Similar Documents

Publication Publication Date Title
CA202905S (en) Half-boot
CA208524S (en) Soundbar
CA196956S (en) Onesie
CA207519S (en) Smartglasses
CA204810S (en) Playard
CA207516S (en) Smartglasses
CA207517S (en) Smartglasses
DK3957371T3 (en) Havaricontainer
CA199411S (en) Handshower
DK4181849T3 (en) Akkvisition-distribution-lag
DK4121781T3 (en) Fiberoptisk accelerationssensor
DK4244933T3 (en) Antennesystem
CA200872S (en) Nighstand
DK4036424T3 (en) Profilsystem
CA206631S (en) Mandoline
EP3889861C0 (en) 3D URL
GB202004207D0 (en) Combinations
GB202001372D0 (en) Bioprinters
CA204263S (en) Brushguard
CA198107S (en) Protractor-ruler
CA212416S (en) Aéronef
CA212654S (en) Velomobile
DK4304956T3 (en) Transportsystem
DK4197885T3 (en) Hydraulisk styresystem
DK4001080T3 (en) Lasthjul

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)